Source: Zhao Ying from Wall Street
This result may change the way kidney disease is treated.
Semigroutide, the "weight-loss medicine", adds another new effectbaccaratbearbrick1000, reduce the risk of death in patients with kidney disease.
On Friday, according to media reports, a new study showed that Novo Nordisk's blockbuster diabetes drug semigroutide Ozempic can not only effectively control blood sugar, but also significantly reduce the risk of death from kidney disease in diabetic patients.
During the study period, patients with kidney disease caused by diabetes were less likely to die by a fifth if they took Ozempic instead of placebo, scientists said in Friday's New England Journal of Medicine.
Last year, Novo Nordisk terminated the trial early after an interim analysis showed significant benefits of the drug, a decision that at one point caused the shares of kidney dialysis service companies Fresenius and DaVita to plummet a total of $3.6 billion.
This finding further confirms Ozempic's potential to alleviate multiple diseases associated with obesity.
Brendon Neuen, director of kidney trials at Royal North Shore Hospital Sydney, said this will undoubtedly be a major positive news and the results may change the treatment of kidney disease.
Vlado Perkovic, co-leader of the study and Executive Vice Chancellor of the University of New South Wales in Sydney, said via email:
The results highlight the close relationship between kidney disease, cardiovascular disease and diabetes, and the fatal consequences of this combination of diseases. The fact that Ozempic can improve all of these conditions and extend the lives of these people isbaccaratbearbrick1000We bring hope.
Obesity often brings many concurrent diseases, which the American Heart Association collectively calls "cardiorenal metabolic syndrome." Rahul Aggarwal, a cardiology researcher at Brigham and Women's Hospital in Boston, said:
Heart disease can lead to kidney disease, kidney disease increases the risk of heart disease, and metabolic disease can also affect all of this.
Although further research still needs to confirm whether Ozempic can become an effective way to treat kidney disease, Novo Nordisk's innovative drug is expected to bring benefits to alleviating multiple metabolic diseases including diabetes and obesity. In the future, its pricing policy and insurance companies 'willingness to pay will determine the number of patients benefiting from the drug.
After the news was released, Novo Nordisk's U.S. stocks fluctuated little before the market.